Menu

去纤维钠医保价格

Author: Medicalhalo
Release time: 2025-10-19 11:44:20

Medical insurance price: Defibrotide sodium, also called defibrotide, is not currently on the market in my country, so it is not included in the national medical insurance, and there is no price after medical insurance.

Defibrotide was marketed by the FDA on March 30, 2016, and is indicated for the treatment of hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), and renal or lung dysfunction in adult and pediatric patients following hematopoietic stem cell transplantation (HSCT). Defibrotide sodium is an adenosine receptor agonist with multiple effects. The adenosine A1/A2 receptors of endothelial cells are involved in the regulation of endothelial cells and the response of endothelial cells to injury. Defibrotide can act on these receptors to produce a variety of downstream effects.

Defibrotide sodium is indicated for both children and adults at a recommended dose of 6.25 mg/kg given every 6 hours as a 2-hour intravenous infusion based on body weight. Defibrotide sodium (Defibrotide) must be diluted before infusion. Do not coadminister with other intravenous medications at the same time and in the same intravenous line.

Studies have shown that defibrinated sodium can significantly increase the expression of thrombin regulatory protein (TM) and tissue factor pathway inhibitors to produce anticoagulant effects. In a clinical trial on the treatment of hepatic veno-occlusive disease in children, the complete response (CR) rate of using defibrotide was 76%, and the overall survival (OS) rate 100 days after transplantation was 64%. The effect is very significant.

(Defibrinoside) has no medical insurance price in my country. The drug has been approved for marketing in some countries or regions such as the United States and the European Union. Its price abroad is around $22,000. The price will change due to various factors such as exchange rates. Patients can consult the medical companion travel service for specific prices.

Recommended related hot articles: /newsDetail/71665.html

[ 免责声明 ]  本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。